News summary
[Zhejiang Pharmaceutical: Notice of Approval for Clinical Trial of LYSC98 for Injection] Securities Times e Company News, Zhejiang Pharmaceutical (600216) announced on the evening of May 27 that the company recently received approval from the State Drug AdministrationplaytoearncryptogamesforfreeApproval Notice for Clinical Trial of LYSC98 Drug for Injection, LYSCplaytoearncryptogamesforfree.playtoearncryptogamesforfree..
Newsletter text
[Zhejiang Pharmaceutical: Notice of Approval for Clinical Trial of LYSC98 for Injection] Securities Times e Company News, Zhejiang Pharmaceutical (600216) announced on the evening of May 27 that the company recently received approval from the State Drug AdministrationplaytoearncryptogamesforfreeLYSC98 (provisional name) is a new generation of new glycopeptides to fight drug-resistant bacteria. It is a compound with glycopeptide structure that has good antibacterial activity against common gram-positive bacteria in clinical practice, especially drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
(: Congratulations